Document:

Form of Nonqualified Stock Option Award Agreement (2010 Award)

 [Note: Text in [ ] is only included in agreements with individuals employed by U.S.
subsidiaries of Tim Hortons Inc., with the exception that text in [ ] in Section 8 is not included in such agreements, but has been included in all other agreements.] 

Exhibit 10(b) 

Form of Nonqualified Stock
Option                              

Award Agreement (2010 Award-NEOs, VPs and Up) 
  

			
	Participant Name (“Grantee”):	  	
		
	Employee Number:	  	
		
	Grant Name:	  	
		
	Date of Grant:	  	May 18, 2010
		
	Expiration Date:	  	[May 15, 2017]
		
	Option Price:	  	Cdn.$                    
		
	Total Award:	  	

  

			
	Vest Schedule – Options
	Vest Date	 	Vest Quantity
	[May 15, 2011]	 	1/3
	[May 15, 2012]	 	1/3
	[May 15, 2013]	 	1/3

 TIM HORTONS INC.

 2006 STOCK INCENTIVE PLAN 

NONQUALIFIED STOCK OPTION AWARD AGREEMENT 

(with related Stock Appreciation Right) 

Grant Year: 2010 

THIS NONQUALIFIED STOCK OPTION AWARD AGREEMENT (this “Agreement”) is made effective as of the
18th day of May, 2010 (the “Date of Grant”), [by
and among/between] Tim Hortons Inc., a corporation incorporated under the Canada Business Corporations Act (the “Company”), [the below-noted Employer,] and the above-noted Grantee (collectively, the “Parties”). 

WHEREAS, the Company has adopted the Tim Hortons Inc. 2006 Stock Incentive Plan, as amended from time to time (the “Plan”), in
order to provide additional incentive compensation to certain employees and directors of the Company and its Subsidiaries; 

WHEREAS, pursuant to Sections 6 and 7 of the Plan, the Human Resource and Compensation Committee (the “Committee”) of the Board
of Directors of the Company (the “Board”) has determined to grant to the Grantee on the Date of Grant a Nonqualified Stock Option and a related Stock Appreciation Right (“SAR”), each as provided herein, to encourage the
Grantee’s efforts toward the continuing success of the Company and its Subsidiaries; and 
 WHEREAS, the Award is evidenced
by this Agreement, which (together with the Plan) describes all the terms and conditions of the Award. 

 NOW, THEREFORE, the Parties agree as follows: 

1. Grant of Award. The Company hereby grants to the Grantee, on the Date of Grant, a Nonqualified Stock Option (the
“Option”) with a related SAR to purchase the above-noted number of Shares at the above-noted exercise price per Share (the “Option Price”), subject to the terms and conditions of this Agreement and the Plan (the
“Award”). The Option is not intended to be treated as an option that complies with Section 422 of the Internal Revenue Code of 1986, as amended. 

2. Vesting; Term of Award. Except as otherwise provided in this Agreement, the Award shall vest as follows: 

(a) One-third (1/3) of the total Shares covered by the Award shall vest on May 15, 2011, subject to rounding down the Award to
the nearest whole Share as of the vesting date; 
 (b) One-third (1/3) of the total Shares covered by the Award shall vest
on May 15, 2012, subject to rounding down the Award to the nearest whole Share as of the vesting date; and 
 (c) One-third
(1/3) of the total Shares covered by the Award shall vest on May 15, 2013, subject to rounding down the Award to the nearest whole Share as of the vesting date. 

The Award shall expire May 15, 2017 (the “Expiration Date”), whether or not the Award (or any portion thereof) has been exercised, unless
sooner terminated as provided in Section 4 of this Agreement. Notwithstanding anything to the contrary contained in this Agreement, if the Award expires outside of a Trading Window, then the expiration of the term of the Award shall be the
later of: (i) the date the Award would have expired by its original terms (including the terms set forth in Section 4 of this Agreement), or (ii) the end of the tenth trading day of the immediately succeeding Trading Window during
which the Company would allow the Grantee to trade in its securities; provided, however, that in no event shall the Award expire beyond the tenth anniversary of the Date of Grant. 

3. Exercise of Award. Subject to the limitations set forth in this Agreement and in the Plan, the vested portion of the Award may
be exercised in whole or in part by providing to the Company or its designee written notice of exercise; provided that the Award may be exercised with respect to whole Shares only. Such notice shall specify (i) whether the Grantee intends to
exercise the Option or the SAR and (ii) the number of Shares with respect to which the Award is to be exercised. 
 (a)
Exercise of SAR. If the Grantee desires to receive cash, as opposed to Shares, upon exercise of all or a portion of the vested amount of the Award, the Grantee will exercise the SAR. Upon the exercise of the SAR, the Grantee shall be entitled
to receive a cash amount from the Company equal to the product of: (i) the excess 
  

 - 2 - 

 
of the Fair Market Value of a Share on the date of exercise of the SAR over the Option Price; multiplied by (ii) the number of Shares as to which the SAR is being exercised. 

(b) Exercise of Option. If the Grantee desires to receive Shares, as opposed to cash, upon exercise of all or a portion of the
vested amount of the Award, the Grantee will exercise the Option. If the Option is exercised, payment of the Option Price for the number of Shares specified in the notice of exercise shall accompany the written notice of exercise. The payment of the
Option Price may be made, as determined by the Committee in its sole discretion as of the time of exercise, as follows: (i) in cash, personal or certified cheque, bank draft or other property acceptable to the Committee; or (ii) through a
cashless exercise, including through a registered broker-dealer. The Committee shall determine the means and manner by which Shares to be delivered upon exercise of the Option shall be settled and/or satisfied, in its sole and absolute discretion.

 (c) Tandem Nature of Award. Upon the exercise of the SAR, the Option shall be canceled (i.e., surrendered to
the Company) to the extent of the number of Shares as to which the SAR is exercised. Upon the exercise of the Option, the SAR shall be canceled (i.e., surrendered to the Company) to the extent of the number of Shares as to which the Option is
exercised or surrendered. 
 4. Termination of Employment. 

(a) Death or Disability. Upon termination of the Grantee’s employment with the Company and its Subsidiaries as a result of the
Grantee’s death or the Grantee becoming Disabled, the Award shall become immediately exercisable as of the Termination Date, and the Grantee (or, to the extent applicable, the Grantee’s legal guardian, legal representative or estate) shall
have the right to exercise the Award for a period of four (4) years after the date of such termination or, if earlier, until the Expiration Date. 

(b) Retirement. Upon termination of the Grantee’s employment with the Company and its Subsidiaries by reason of the
Grantee’s Retirement (as defined below), for a period of four (4) years following the date of such Retirement (but in no event beyond the Expiration Date), the Award shall remain outstanding and (i) to the extent not then fully
vested, shall continue to vest in accordance with the vesting schedule set forth in Section 2 of this Agreement, and (ii) the Grantee shall have the right to exercise the vested portion of the Award. For purposes of this Agreement,
“Retirement” shall mean termination of employment after attaining age sixty (60) with at least ten (10) years of service other than by death, Disability or for Cause. 

(c) Termination in Connection with Certain Dispositions. In the event the Grantee’s employment with the Company and its
Subsidiaries is terminated without Cause in connection with a sale or other disposition of a Subsidiary, the Award shall remain outstanding and (i) to the extent not then fully vested, will become immediately vested on the Termination Date, and
(ii) the Grantee will have the right to exercise such 
  

 - 3 - 

 
vested portion of the Award for a period of one (1) year following the Termination Date or, if earlier, until the Expiration Date. 

(d) Termination for Cause. For greater clarity, upon the termination of the Grantee’s employment with the Company and its
Subsidiaries for Cause, the portion of the Award that has not been exercised shall be forfeited (whether or not then vested and exercisable) on the Termination Date. 

(e) Termination for Any Other Reason. Upon the termination of the Grantee’s employment with the Company and its Subsidiaries
for any reason not described in Section 4(a), 4(b), 4(c), or 4(d) of this Agreement, the Award shall (i) to the extent not vested and exercisable as of the Termination Date, terminate as of the Termination Date, and (ii) to the extent
vested and exercisable as of the Termination Date, remain exercisable for a period of ninety (90) days following the Termination Date or, in the event of the Grantee’s death during such ninety (90) day period, remain exercisable by
the Grantee’s estate until the end of one (1) year period following the Termination Date; provided, however, that, in either case, the Award shall not remain exercisable beyond the Expiration Date. 

5. Effect of Change in Control. In the event of a Change in Control, Section 11.6 of the Plan will apply to the unvested
portion of the Award. 
 6. Non-Transferability of Award. Except to the extent that the Grantee’s legal
representative or estate is permitted to exercise the Award pursuant to the terms of the Plan or in accordance with a determination of the Committee, the Award is exercisable only during the Grantee’s lifetime and only by the Grantee. Unless
otherwise provided for by a determination of the Committee, the Award shall not be transferable except by will or the laws of descent and distribution. 

7. No Right to Continued Employment. Nothing in this Agreement or the Plan shall interfere with or limit in any way the right of
the Company or its Subsidiaries to terminate the Grantee’s employment, nor be construed as giving the Grantee any right to continuance of employment by the Company or any of its Subsidiaries or continuance of service to the Company or any of
its Subsidiaries. 
 8. Withholding of Taxes. Upon the exercise of the Award, the Company [(or in the case of a Grantee
employed by a Subsidiary (the “Employer”))], the Employer, or a trust established to deliver Shares under an Award (“Trust”), as applicable, shall require payment of or other provision for, as determined by the Company, an amount
equal to the federal, state, provincial and local income taxes and other amounts required by law to be withheld or determined to be necessary or appropriate to be withheld by the Company, the Employer, or Trust, as applicable, in connection with
such exercise. In its sole discretion, the Company, the Employer, or Trust, as applicable, may require or permit payment of or provision for such withholding taxes through one or more of the following methods: (a) in cash, bank draft, certified
cheque, personal cheque or other manner acceptable to 
  

 - 4 - 

 
the Committee and/or set forth in the relevant exercise procedures; (b) by withholding such amount from other amounts due to the Grantee; (c) by withholding a portion of the Shares then
issuable or deliverable to the Grantee having an aggregate fair market value equal to such withholding taxes and, at the Company’s election, either (I) canceling the equivalent portion of the underlying Award and the Company, the Employer,
or Trust paying the withholding taxes on behalf of the Grantee in cash, or (II) selling such Shares on the Grantee’s behalf; or (d) by withholding such amount from the cash then issuable in connection with the Award. [The Grantee
acknowledges and agrees that, notwithstanding that the Employer is not a party to this Agreement, the Employer, if applicable, shall be entitled to take such actions provided for in this Section as the Employer shall deem appropriate.] 

9. Grantee Bound by Plan; Award Subject to Terms of Plan. The Grantee hereby acknowledges receipt of a copy of the Plan and agrees
to be bound by all the terms and provisions thereof. This Agreement shall be construed in accordance and consistent with, and is subject to, the provisions of the Plan (the provisions of which are hereby incorporated by reference), as well as any
and all determinations, policies, instructions, interpretations and rules of the Committee in connection with the Plan, including the Option/SAR Exercise and Settlement Policy and related procedures adopted by the Committee. Except as otherwise
expressly set forth herein, the capitalized terms used in this Agreement shall have the same definitions as set forth in the Plan. 

10. Modification of Agreement. The Board or Committee may make amendments or changes to this Award, subject to the terms
and conditions of Section 22 of the Plan. 
 11. Severability. Should any provision of this Agreement be held
by a court of competent jurisdiction to be unenforceable or invalid for any reason, the remaining provisions of this Agreement shall not be affected by such holding and shall continue in full force in accordance with their terms. 

12. Governing Law. The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of
the Province of Ontario and the federal laws of Canada applicable therein. 
 13. Successors in Interest and Assigns. The
Company and the Employer may assign any of their respective rights and obligations under this Agreement without the consent of the Grantee. This Agreement shall inure to the benefit of and be binding upon any successors and assigns of the Company
and the Employer. This Agreement shall inure to the benefit of the successors of the Grantee including, without limitation, the estate of the Grantee and the executor, administrator or trustee of such estate. All obligations imposed upon the Grantee
and all rights granted to the Company and the Employer under this Agreement shall be binding upon the successors of the Grantee including, without limitation, the estate of the Grantee and the executor, administrator or trustee of such estate.

  

 - 5 - 

 14. Resolution of Disputes. Any dispute or disagreement which may arise under, or as
a result of, or in any way relate to, the interpretation, construction or application of this Agreement shall be determined by the Committee. Any determination made hereunder shall be final, binding and conclusive on the Grantee, the Grantee’s
heirs, executors, administrators and successors, and the Company and its Subsidiaries for all purposes. 
 15. Entire
Agreement. This Agreement and the terms and conditions of the Plan constitute the entire understanding between the Grantee and the Company and its Subsidiaries, and supersede all other agreements, whether written or oral, with respect to the
Award. 
 16. Headings. The headings of this Agreement are inserted for convenience only and do not constitute a part of
this Agreement. 
 17. Counterparts. This Agreement may be executed simultaneously in two or more counterparts, each of
which shall constitute an original, but all of which taken together shall constitute one and the same agreement. 
 18.
Recoupment Policy upon Restatement of Financial Results. The Award, and any proceeds therefrom, is subject to the Company’s right to reclaim its benefits in the event of a financial restatement pursuant to the Recoupment Policy Relating
to Performance-Based Compensation (the “Recoupment Policy”) adopted by the Board, as may be amended from time to time. If the Company’s financial statements are required to be restated for any reason (other than restatements due to
changes in accounting policy with retroactive effect), the Board will review the Award earned by the Grantee. If the Board determines that, after a review of all of the relevant facts and circumstances, the grant of the Award was predicated upon the
achievement of certain financial results that were subsequently corrected as part of a restatement and a lower Award would have been made to the Grantee based upon the restated financial results; then, the Board will seek recoupment of the Award to
the extent that the Board deems appropriate. 
 19. Language. The Parties hereto acknowledge that they have
requested that this Agreement and all documents ancillary thereto, including all the documentation provided to the Grantee in respect of the Award, be drafted in the English language only. Les parties aux présentes reconnaissent
qu’elles ont exigé que la présente convention et tous les documents y afférents, y compris toute la documentation transmise au bénéficiaire relativement à l’octroi des droits prévu aux
présentes, soient rédigés en langue anglaise seulement. 
 20. Accessing Information. A copy of
the Plan and prospectus for the Plan, as may be amended, can be found by the Grantee by accessing his/her Solium Shareworks account at www.solium.com. That site also contains other general information about the Award. 

 

 - 6 - 

 21. Confirming Information. By accepting this Agreement, either through electronic
means or by providing a signed copy, the Grantee (i) acknowledges and confirms that he/she has read and understood the Plan, the related prospectus, this Agreement and all information about the Award available at the Solium website, and that
he/she has had an opportunity to seek separate fiscal, legal and taxation advice in relation thereto; (ii) acknowledges that he/she has been provided with a copy of the Annual Report on Form 10-K for the most recently completed fiscal year of
the Company; (iii) agrees to be bound by the terms and conditions stated in this Agreement, including without limitation the terms and conditions of the Plan, incorporated by reference herein; and (iv) acknowledges and agrees that
acceptance through electronic means is equivalent to doing so by providing a signed copy. 
  

			
	TIM HORTONS INC.
		
	By:	 	  

		
	Name:	 	  

		
	Title:	 	  

	
	[(“Employer”)]

  

 - 7 -Amendment No. 1 dated November 11, 2009 to Sublease Agreement

 Exhibit 10.12.2 

AMENDMENT NO. 1 

TO 

SUBLEASE AGREEMENT 

RESEARCH PARK BUILDING - PHASE V 

THIS AMENDMENT NO. 1 TO SUBLEASE AGREEMENT (the “First Amendment”) is made and entered into effective as of November 11,
2009 by and between Myriad Genetics, Inc. (the “Landlord”), and Myriad Pharmaceuticals, Inc. (the “Tenant”). 

WHEREAS, Landlord and Tenant entered into that certain Sublease Agreement, dated effective as of July 1, 2009, with respect to the
Leased Premises in the Building located on the Property; 
 WHEREAS, Paragraph 1.4 of the Sublease Agreement provides for Tenant
to be responsible for, and to otherwise pay for, certain Tenant Finish costs with respect to the Leased Premises; and 

WHEREAS, Tenant desires that Landlord fund, or otherwise pay for, a portion of the Tenant Finish costs in exchange for which Tenant is
willing to pay Landlord additional rent for the Leased Premises over a specified period of time. 
 NOW THEREFORE, in
consideration of the premises set forth herein, and for such other good and valuable consideration the sufficiency of which is hereby acknowledged, Landlord and Tenant agree as follows. 

1. Capitalized Terms. All capitalized terms shall have the same meaning ascribed to such capitalized terms as provided for under
the Sublease Agreement and Exhibits thereto. 
 2. Tenant Finish. Tenant represents that it has approved the Tenant
Finish Plans and the estimated Tenant Finish budget as contemplated in Exhibits C and E, respectively, to the Sublease Agreement. Landlord shall pay up to $4,256,864.32 for Tenant Finish work to the Leased Premises as provided for under the Tenant
Finish Plans. As Tenant Finish work to the Leased Premises is completed and draws for the same are invoiced by third parties, Tenant shall review and approve the Tenant Finish work and related third party invoices, and Tenant shall then present to
Landlord reasonable evidence of the completion of such Tenant Finish work and provide copies of the applicable third party invoices which have been approved by Tenant. Landlord shall review such required documentation and then pay the applicable
third party for the invoiced amounts as approved by Landlord which approval shall not be unreasonably withheld. The total amount approved and paid to third parties by Landlord for the Tenant Finish work shall not exceed $4,256,864.32. Tenant remains
responsible for all remaining Tenant Finish costs. 
 3. Additional Rent. In addition to all other amounts due and
payable under the Sublease Agreement, there shall be an additional amount paid, as rent for the use of the 

 
Leased Premises, as completed with the Tenant Finish, of $78,861.98 per month (the “Additional TI Rent”) during the initial term of the Lease and, if the lease term is extended, for the
first three year option period. The Tenant’s obligation to pay the Additional TI Rent shall begin on the Commencement Date. Thereafter, each monthly Additional TI Rent amount shall be due and payable on the first day of each calendar month
during the term of the Sublease Agreement. The Additional TI Rent payment shall be subject to a pro rata adjustment, based on the number of days occupied during any partial month in which the Leased Premises is occupied by the Tenant. 

4. Conclusion of Lease Term. The Tenant Finish shall become part of the Leased Premises, and upon termination of the Lease, Tenant
shall have no rights to the Tenant Finish except as set forth in Exhibit F to the Sublease Agreement. 
 5. Sublease
Agreement. All other terms and conditions, including those provided for in the Exhibits, of the Sublease Agreement, except to the extent modified by the terms of this First Amendment, shall continue in full force and effect, including
Landlord’s rights and remedies for the failure to pay any rents due under the Sublease Agreement, as amended. 
 6. No
Other Approvals. Landlord and Tenant agree that no other third party approvals of this First Amendment shall be sought, or need to be obtained, for this First Amendment to be effective and binding on Landlord and Tenant. 

IN WITNESS WHEREOF, the duly authorized representative of Landlord and of Tenant have signed this First Amendment effective as of the
date first set forth above. 
  

					
	 	 	MYRIAD GENETICS, INC.
		
		 	 /s/ Peter D. Meldrum

		 	BY:	 	Peter D. Meldrum
		 	ITS:	 	President and CEO
		
		 	MYRIAD PHARMACEUTICALS, INC.
		
		 	 /s/ Adrian Hobden

		 	BY:	 	Adrian Hobden, Ph.D.
		 	ITS:	 	President and CEO

  

 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00177-of-00352.parquet"}]]